Thryv Therapeutics Inc.
LightNews LightNews
banner
thryvtrx.bsky.social
Thryv Therapeutics Inc.
@thryvtrx.bsky.social
13 followers 30 following 22 posts
We will relentlessly pursue a precision medicine approach targeting SGK1 to enable people to live their best lives. Without limits.

Visit our website: https://thryvtrx.com/
Posts Replies Media Videos
thryvtrx.bsky.social
Exciting updates from #AHA25! 🎉

Our CMO, Dr. Amy Sehnert, and co-founder, Dr. Saumya Das, presented 3 posters on SGK1 inhibition in heart failure.

Our new preprint, “A novel SGK1 inhibitor improves cardiac structure & function”, is now live: researchsquare.com/article/rs-7...

#HeartFailure #SGK1
November 11, 2025 at 7:15 PM
thryvtrx.bsky.social
Thryv Therapeutics will present 3 moderated e-posters at #AHA25 on THRV-1268, part of our SGK1 inhibitor portfolio targeting heart failure & cardiac remodeling.

📍 Nov 8–10 | New Orleans

Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
November 5, 2025 at 2:59 PM
thryvtrx.bsky.social
Thryv Therapeutics will join the Wells Fargo, Stifel, Jefferies & RBC investor conferences to share our vision for transforming cardiovascular care through SGK1 inhibition.

👉 Read more: loom.ly/tUk3fWY

#ThryvTherapeutics #SGK1 #Biotech #LQTS #AFib #HeartFailure
November 3, 2025 at 2:30 PM
thryvtrx.bsky.social
With FDA IND clearance and investor backing, Thryv is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 for Long QT Syndrome—bringing us closer to the first approved therapy for people with LQTS.

👉 loom.ly/tZj96M8

#SGK1 #LQTS #Biotech
September 17, 2025 at 6:53 PM
thryvtrx.bsky.social
📣 We’re headed to #ESCCongress! Excited to share compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268.

🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini

Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
August 26, 2025 at 3:29 PM
thryvtrx.bsky.social
🔬 Behind the scenes in the lab!
Our team is advancing SGK1 inhibition to help treat LQTS, AFib & heart failure. From bench to breakthrough.
#SGK1 #CardiacResearch #TeamThryv
August 26, 2025 at 3:28 PM
thryvtrx.bsky.social
🌍 On #ClinicalTrialsDay, we celebrate the power of research—especially in rare diseases, where each trial brings hope. Thank you to the patients, researchers & HCPs driving progress.

At Thryv, we’re proud to advance treatments for LQTS, heart failure & AF. 💚

#ResearchMatters
May 20, 2025 at 5:29 PM
thryvtrx.bsky.social
Thryv to share latest clinical results of SGK1 inhibition in patients with LQTS at RBC (May 20–21) & Jefferies (June 3–5). Learn more about our SGK1 platform for LQTS, HF & AFib.

📄 Press release: loom.ly/sIJ8l0c
📩 admin@thryvtrx.com

#ThryvTherapeutics #SGK1 #LQTS
May 13, 2025 at 1:12 PM
thryvtrx.bsky.social
👩‍⚕️ Nurses are the heart of healthcare. On this #InternationalNursesDay, we recognize their power to shape stronger health systems.

At Thryv, we’re proud to work with nurses advancing cardiovascular care and clinical research. 💚

#ThankYouNurses #NursesTransformCare
May 12, 2025 at 1:24 PM
thryvtrx.bsky.social
May is #StrokeAwarenessMonth. Stroke is the most serious complication of #AFib, increasing risk 5x. At Thryv, we’re targeting SGK1 to address the biology behind AFib. Know the signs:
👤 Face drooping
💪 Arm weakness
🗣️ Speech trouble
📞 Time to call 911. #FAST #HeartHealth
May 5, 2025 at 3:43 PM
thryvtrx.bsky.social
📣 Join us Sunday at #HRS2025!
🗓️ Apr 27 | 8–9 AM PT
📍 Hub 4 – Sails Pavilion, SDCC
👨‍⚕️ Dr. Philip Sager presents new clinical data from Wave I, Part 2: SGK-1 Inhibition with LQT-1213 Significantly Reduces QTcF in Patients with Congenital Long QT Syndrome

#LQTS #SGK1
April 23, 2025 at 2:49 PM
thryvtrx.bsky.social
We’re proud to have a team of innovators from both sides of the border advancing treatments for Long QT Syndrome, heart failure & AFib.

With the FDA, we're united in bringing new options to those living with cardiovascular disease. 💚

#TeamThryv #LQTS #SGK1 #Biotech
April 14, 2025 at 12:29 AM
thryvtrx.bsky.social
Thryv Therapeutics is excited to join the 2025 Piper Sandler Virtual Cardio Day on April 1! Our leadership team will sit for a fireside chat at 11:30 a.m. ET, sharing insights on SGK1 inhibition for LQTS, HF & AFib.

📢 Read more: thryvtrx.com/news/piper-s...

#PiperSandler #SGK1 #BioTech
March 27, 2025 at 6:47 PM
thryvtrx.bsky.social
Heart failure (HF) affects millions, yet HFpEF remains difficult to treat. Many patients have obesity, hypertension, or AFib.

SGK1 may play a key role, and we’re exploring its inhibition as a potential treatment. Stay tuned for more research updates. ❤️

#HeartFailure #HFpEF #SGK1 #HeartResearch
February 27, 2025 at 4:21 PM
thryvtrx.bsky.social
💓 This Week, We’re Talking About AFib! #HeartMonth

AFib affects 5M+ Americans & 200K Canadians, increasing stroke & heart failure risk. Causes include high BP, heart disease, sleep apnea & aging. Symptoms range from palpitations to silent AFib.

#AFib #ThryvTherapeutics #SGK1
February 25, 2025 at 2:54 PM
thryvtrx.bsky.social
This week, we’re talking about heart failure 🫀 #HeartMonth

HF affects 6M+ Americans & 750K Canadians. Causes include high blood pressure, heart attacks, & diabetes. Early diagnosis & research improve outcomes.

#HeartFailure #ThryvTherapeutics
February 21, 2025 at 7:47 PM
thryvtrx.bsky.social
❤️ CPR Saves Lives ❤️

Looking back on our 2023 CPR training! 📸 When the heart stops, every second counts—CPR can triple survival rates. For those with LQTS & other heart conditions, knowing CPR can save a life! 💡

#CPRSavesLives #HeartHealth #LQTSAwareness #HeartMonth
February 11, 2025 at 3:50 PM
thryvtrx.bsky.social
Did you know? 🫀 CVDs are the leading cause of death globally, with ~19.91M deaths in 2021 (AHA). Many are preventable with early detection & lifestyle changes! This #HeartMonth, let’s raise awareness & drive innovation in heart health. ❤️🔬 #HeartHealth #HeartMonth2025 #SGK1
February 4, 2025 at 3:10 PM
thryvtrx.bsky.social
Thryv Therapeutics is looking forward to participating in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL Join us March 10-12 to discuss the latest advancements on our cardiovascular programs.

Schedule a meeting: admin@thryvtrx.com

#ThryvTherapeutics #Biotech #LeerinkPartners
February 3, 2025 at 3:16 PM
thryvtrx.bsky.social
February is #HeartMonth! 🫀 Let’s raise awareness about heart disease— the leading cause of death worldwide.

At Thryv, we're advancing heart health with SGK1 inhibition as a treatment for LQTS, heart failure, and AFib! ❤️💡

Stay tuned for more!

#HeartHealth #SGK1 #HeartMonth2025 #ThryvTherapeutics
January 31, 2025 at 3:39 PM
thryvtrx.bsky.social
#JPM2025 is just around the corner. Thryv Therapeutics is looking forward to attending this premier event in San Francisco, January 13-16, 2025. To schedule a meeting: admin@thryvtrx.com

#JPMWeek #BiotechInnovation #CardiovascularHealth #ThryvTherapeutics #SGK1
January 8, 2025 at 5:39 PM
thryvtrx.bsky.social
📣 Thryv Therapeutics is excited to attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 13-16, 2025! Looking forward to connecting and sharing updates on our cardiovascular therapies. 💚

Read more: thryvtrx.com/news/jp-morg...

#JPM2025 #Biotech #CardiovascularHealth #SGK1
December 18, 2024 at 4:19 PM